Lymphoma Research Studies
We are currently conducting the following research studies for people with lymphoma:
The EPCORE NHL-5 Study is evaluating the safety and tolerability of a primary investigational drug in combination with other drugs for adults with non-Hodgkin lymphoma.
The EPCORE FL-2 Study is evaluating the safety and effectiveness of an investigational drug in combination with a chemotherapy-free regimen compared to standard-of-care chemoimmunotherapy for adults with newly diagnosed follicular lymphoma.
The EPCORE DLBCL-4 Study is evaluating the safety and effectiveness of a study drug in combination with an approved anti-lymphoma drug compared to standard-of-care treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Although the study drug is approved for treating certain patients with DLBCL, its use in this study is considered investigational since its safety and effectiveness for the intended investigational purpose have not yet been established.
The EPCORE NHL-6 Study is evaluating the safety and efficacy of an investigational drug for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) for potential use in an outpatient (non-hospital) setting.
The EPCORE PEDS-1 Study is evaluating the safety, tolerability, pharmacokinetics (what the body does to the drug), and preliminary efficacy of an investigational drug in children, teens, and young adults with aggressive forms of mature B-cell non-Hodgkin lymphoma (NHL).
The EPCORE DLBCL-2 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
The EPCORE FL-1 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with relapsed or refractory follicular lymphoma.
The EPCORE NHL-6 Study is evaluating the safety and efficacy of an investigational drug for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or classic follicular lymphoma (cFL) for potential use in an outpatient (non-hospital) setting.
The EPCORE FL-1 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with relapsed or refractory follicular lymphoma.
The EPCORE PEDS-1 Study is evaluating the safety, tolerability, pharmacokinetics (what the body does to the drug), and preliminary efficacy of an investigational drug in children, teens, and young adults with aggressive forms of mature B-cell non-Hodgkin lymphoma (NHL).
The EPCORE DLBCL-2 Study is evaluating the safety and efficacy of an investigational drug in combination with standard-of-care drugs for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
The investigational drug being evaluated in these studies is a molecule that can attach to proteins on 2 types of white blood cells: T-cells and B-cells, cells that help the body fight infections. One side of the investigational drug attaches to a protein on T-cells and the other side attaches to a protein on B-cells. By connecting at the same time to these cells, the investigational drug directs the T-cells to kill the B-cells, including the cancerous B-cells. This may help eliminate the cancer cells in non-Hodgkin lymphoma.
